Olivier Vanloocke

Olivier Vanloocke is an experienced executive in the biopharmaceutical and vaccine manufacturing industry, currently serving as CEO of CER Groupe since March 2021. Prior to this role, Olivier operated as a Senior Operations Consultant, where consultant work included establishing Curevac's Covid-19 mRNA vaccine manufacturing network and serving as interim COO for BePharbel Manufacturing. Olivier's extensive tenure at GSK Vaccines spanned 25 years, culminating in the position of Senior Director of Primary Operations with accountability for a large workforce and multi-product manufacturing units. Key achievements at GSK include leading operational strategies, implementing lean manufacturing programs, and successful capital investment projects aimed at enhancing operational efficacy and regulatory compliance. Olivier's career began as a veterinary practitioner after earning a Doctorate in Veterinary Medicine from the University of Liège.